Medication adherence in patients with rheumatoid arthritis: A critical appraisal of the existing literature

Expert Review of Clinical Immunology

Volumn 8, Issue 4, 2012, Pages 337-351

  Van Den Bemt, Bart J F ^a   Zwikker, Hanneke E ^a   Van Den Ende, Cornelia H M ^a  

^a Sint Maartenskliniek ^*  (Netherlands)

Author keywords

adherence; beliefs about medication; compliance; DMARDs

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

DRUG EFFICACY; HEALTH CARE SYSTEM; NANOMEDICINE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; QUESTIONNAIRE; REVIEW; RHEUMATOID ARTHRITIS; SOCIOECONOMICS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MEDICATION ADHERENCE; PATIENT COMPLIANCE; RISK FACTORS;

EID: 84861397647     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.23     Document Type: Review

References (79)

1. Horne R, Weinman J. Predicting treatment adherence: An overview of theoretical models. In: Adherence to Treatment in Medical Conditions. Myers LB, Midence K (Eds). Harwood Academic Press, Amsterdam, The Netherlands, 25-50 (1998).
2. Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med. 353(5), 487-497 (2005).
3. Lewis A. Noncompliance: A $100 billion problem. Remington Report 5, 14-15 (1997).
4. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database Syst. Rev. 4, CD000011 (2005) (Review). Update in: Cochrane Database Syst. Rev. 2, CD000011 (2008).
5. Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M. The effect of treatment on radiological progression in rheumatoid arthritis: A systematic review of randomized placebo-controlled trials. Rheumatology 42, 6-13 (2003).
6. Contreras-Yáñez I, Ponce De León S, Cabiedes J, Rull-Gabayet M, Pascual- Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am. J. Med. Sci. 340(4), 282-290 (2010).
7. Viller F, Guillemin F, Briançon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance to drug treatment of patients with rheumatoid arthritis: A 3 year longitudinal study. J. Rheumatol. 26, 2114-2122 (1999).
8. Belcon MC, Haynes RB, Tugwell P. A critical review of compliance studies in rheumatoid arthritis. Arthritis Rheum. 27(11), 1227-1233 (1984).
9. Dunbar J, Dunning EJ, Dwyer K. Compliance measurement with arthritis regimen. Arthritis Care Res. 2(3), S8-S16 (1989).
10. Elliott RA. Poor adherence to medication in adults with rheumatoid arthritis reasons and solutions. Dis. Manage. Health Outcomes 16, 13-29 (2008).
11. De Klerk E, van Der Heijde D, Landewé R, van Der Tempel H, Urquhart J, van Der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J. Rheumatol. 30, 44-54 (2003).
12. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR. Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. Arthritis Care Res. 62(5), 730-734 (2010).
13. Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr. Med. Res. Opin. 25(6), 1365-1377 (2009).
14. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum. 59(10), 1519-1526 (2008).
15. van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J. Rheumatol. 36(10), 2164-2170 (2009).
16. Doyle DV, Perrett D, Foster OJ, Ensor M, Scott DL. The long-term use of d-penicillamine for treating rheumatoid arthritis: Is continuous therapy necessary? Br. J. Rheumatol. 32, 614-617 (1993).
17. Pullar T, Peaker S, Martin MF, Bird HA, Feely MP. The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. Br. J. Rheumatol. 27, 381-384 (1988).
18. Brus H, van De Laar M, Taal E, Rasker J, Wiegman O. Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations. Patient Educ. Couns. 36, 57-64 (1999).
19. Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol. Int. 27(8), 743-746 (2007).
20. Owen SG, Friesen WT, Roberts MS, Flux W. Determinants of compliance in rheumatoid arthritic patients assessed in their home environment. Br. J. Rheumatol. 24(4), 313-320 (1985).
21. Deyo RA, Inui TS, Sullivan B. Noncompliance with arthritis drugs: Magnitude, correlates, and clinical implications. J. Rheumatol. 8(6), 931-936 (1981).
22. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin. Rheumatol. 27(7), 883-889 (2008).
23. Sackett DL, Haynes RB. Compliance with Therapeutic Regimens. John Hopkins University Press, London, UK (1976).
24. Treharne GJ, Lyons AC, Hale ED, Douglas KM, Kitas GD. 'Compliance' is futile but is 'concordance' between rheumatology patients and health professionals attainable? Rheumatology 45(1), 1-5 (2006).
25. Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A narrative review of the literature. Orthop. Nurs. 29(4), 260-275 (2010).
26. Arluke A. Judging drugs: patients' conceptions of therapeutic efficacy in the treatment of arthritis. Hum. Organ. 39(1), 84-88 (1980).
27. De Klerk E. Measurement of patient compliance on drug therapy: An overview. In: Advances in Behavioral Medicine Assessment. Vingerhoets A (Ed.). Harwood Academic Publishers, London, UK, 215-244 (2001).
28. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am. J. Hypertens. 19(11), 1190-1196 (2006).
29. Staples B, Bravender T. Drug compliance in adolescents: Assessing and managing modifiable risk factors. Paediatr. Drugs 4(8), 503-513 (2002).
30. Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann. Pharmacother. 38, 303-312 (2004).
31. Roth HP, Caron HS. Accuracy of doctors 'estimates and patients' statements on adherence to a drug regimen. Clin. Pharmacol. Ther. 23, 361-370 (1978).
32. Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. Can. Med. Assoc. J. 123, 119-1122 (1980).
33. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol. Drug Saf. 15(8), 565-574 (2006).
34. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: A proposal for standard definitions and preferred measures. Ann. Pharmacother. 40(7-8), 1280-1288 (2006).
35. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. J. Am. Med. Assoc. 261, 3273-3277 (1989).
36. Schwed A, Fallab CL, Burnier M et al. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J. Clin. Pharmacol. 39, 402-409 (1999).
37. McKenney JM, Munroe WP, Wright JT Jr. Impact of an electronic medication compliance aid on long-term blood pressure control. J. Clin. Pharmacol. 32, 277-283 (1992).
38. Waeber B, Vetter W, Darioli R, Keller U, Brunner HR. Improved blood pressure control by monitoring compliance with antihypertensive therapy. Int. J. Clin. Pract. 53, 37-38 (1999).
39. Hill J. Adherence with drug therapy in the rheumatic diseases part two: Measuring and improving adherence. Musculoskeletal Care 3(3), 143-156 (2005).
40. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care. 24, 67-74 (1986).
41. Horne R. Compliance, adherence, and concordance: Implications for asthma treatment. Chest 130, S65-S72 (2006).
42. De Klerk E, van Der Heijde D, van Der Tempel H, van Der Linden S. Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J. Rheumatol. 26, 2635-2641 (1999).
43. De Klerk E, van Der Heijde D, Landewé R, van Der Tempel H, van Der Linden S. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: A validation study. J. Rheumatol. 30, 2469-2475 (2003).
44. Sewitch MJ, Dobkin PJ, Bernatsky S et al. Medication nonadherence in women with fibromyalgia. Rheumatology 43, 648-654 (2004).
45. Butler JA, Peveler RC, Roderick PJ, Horne R, Mason JC. Measuring compliance to drug regimes following renal transplantation: A comparison of self-report and clinician rating with electronic monitoring. Transplantation 77, 786-789 (2004).
46. Arnsten JH, Demas PA, Farzadegan H et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-reported and electronic monitoring. Clin. Infect. Dis. 33, 1417-1423 (2001).
47. Hugen PW, Langebeek N, Burger DM et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J. Acquir. Immune Defic. Syndr. 30, 324-334 (2002).
48. Bangsberg DR, Hecht FM, Charlebois ED et al. Adherence to protease inhibitors, HIV- 1 viral load, and development of drug resistance in an indigent population. AIDS 14, 357-366 (2000).
49. Liu H, Golin CE, Miller LG et al. Comparison study of multiple measures of adherence to HIV protease inhibitors. Ann. Intern. Med. 134, 968-977 (2001).
50. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch. Intern. Med. 150(7), 1509-1510 (1990).
51. van Dulmen S, Sluijs E, van Dijk L, De Ridder D, Heerdink R, Bensing J. International expert forum on patient adherence. Furthering patient adherence: A position paper of the International Expert Forum on Patient Adherence based on an internet forum discussion. BMC Health Serv. Res. 27(8), 47 (2008).
52. Treharne GJ, Lyons AC, Kitas GD. Medication adherence in rheumatoid arthritis: effects of psychosocial factors. Psychol. Health Med. 9, 337-349 (2004).
53. Park DC, Hertzog C, Leventhal H et al. Medication adherence in rheumatoid arthritis patients: older is wiser. J. Am. Geriatr. Soc. 47, 172-183 (1999).
54. Kumar K, Gordon C, Toescu V et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: A comparison between patients of south Asian and White British origin. Rheumatology (Oxford) 47(5), 690-697 (2008).
55. Rogers PG, Bullman W. Prescription medicine compliance: Review of the baseline of knowledge - report of the National Council on Patient Information and Education. J. Pharmacoepidemiol. 3, 3-36 (1995).
56. Beckles GL et al. Population-based assessment of the level of care among adults with diabetes in the U.S. Diabetes Care 21, 1432-1438 (1998).
57. Lorish CD, Richards B, Brown S. Missed medication doses in rheumatic arthritis patients: Intentional and unintentional reasons. Arthritis Care Res. 2(1), 3-9 (1989).
58. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23(8), 1296-1310 (2001).
59. Ammassari A, Trotta MP, Murri R et al.; AdICoNA Study Group. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J. Acquir. Immune Defic. Syndr. 15(Suppl. 3), S123-S127 (2002).
60. Cameron C. Patient compliance: Recognition of factors involved and suggestions for promoting compliance with therapeutic regimens. J. Adv. Nurs. 24(2), 244-250 (1996).
61. Lorish CD, Richards B, Brown S Jr. Perspective of the patient with rheumatoid arthritis on issues related to missed medication. Arthritis Care Res. 3(2), 78-84 (1990).
62. Horne R. Representations of medication and treatment: Advances in theory and assessment. In: Perceptions of Health and Illness. Petrie KJ, Weinman J (Eds). Harwood, Chur, Switzerland, 155-188 (1997).
63. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom. Res. 47, 555-567 (1999).
64. Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: Application of the necessity-concerns framework. J. Psychosomat. Res. 64, 41-46 (2008).
65. Wroe AL. Intentional and unintentional nonadherence: A study of decision making. J. Behav. Med. 25, 355-372 (2002).
66. Wroe AL, Thomas MG. Intentional and unintentional nonadherence in patients prescribed HAART treatment regimens. Psychol. Health Med. 8, 453-463 (2003).
67. Rosenstock IM. Why people use health services. Milbank Mem. Fund Q. 44(3 Suppl.), 94-127 (1966).
68. van den Bemt BJ, van Lankveld WG. How can we improve adherence to therapy by patients with rheumatoid arthritis? Nat. Clin. Pract. Rheumatol. 3(12), 681 (2007).
69. Neame R, Hammond A. Beliefs about medications: A questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford) 44(6), 762-767 (2005).
70. van Dijk L, Heerdink ER, Somai D et al. Patient risk profiles and practice variation in nonadherence to antidepressants, antihypertensives and oral hypoglycemics. BMC Health Serv. Res. 10(7), 51 (2007).
71. No authors listed. Interventions to improve patient adherence with medications for chronic cardiovascular disorders, special report. TEC Bull. (Online) 20, 30-32 (2003).
72. Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence: Review of recent literature. J. Clin. Psychopharmacol. 23, 389-399 (2003).
73. Riemsma RP, Kirwan J, Rasker J, Taal E. Patient education for adults with rheumatoid arthritis. Cochrane Database Syst. Rev. 2, CD003688 (2003).
74. Hill J, Bird H, Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: A randomised controlled trial. Ann. Rheum. Dis. 60(9), 869-875 (2001).
75. Brus HLM, van De Laar MAFJ, Taal E, Rasker JJ, Wiegman O. Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. Ann. Rheumat. Dis. 57, 146-151 (1998).
76. van den Bemt BJ, den Broeder AA, van den Hoogen FH et al. Making the rheumatologist aware of patients' non-adherence does not improve medication adherence in patients with rheumatoid arthritis. Scand. J. Rheumatol. 40(3), 192-196 (2011).
77. Wetzels G, Nelemans P, van Wijk B, Broers N, Schouten J, Prins M. Determinants of poor adherence in hypertensive patients: development and validation of the 'Maastricht Utrecht Adherence in Hypertension (MUAH)- questionnaire'. Patient Educ. Couns. 64, 151-158 (2006).
78. Misselbrook D. Why do patients decide to take their medicines? Prescriber 9(7), 41-44 (1998).
79. Taal E, Riemsma RP, Brus HL, Seydel ER, Rasker JJ, Wiegman O. Group education for patients with rheumatoid arthritis. Patient Educ. Couns. 20(2-3), 177-187 (1993).